Source: The Wall Street Journal
Summary
Patients are suing manufacturers of GLP-1 receptor agonists, alleging the drugs may increase the risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare cause of sudden vision loss. The American Academy of Ophthalmology describes NAION as an “eye stroke.” Novo Nordisk and Eli Lilly have disputed the claims, citing research showing no increased risk. A 2024 Harvard study found a fourfold higher relative risk of NAION in patients taking semaglutide, though absolute risk remains low. The FDA is reviewing evidence, and the European Medicines Agency has recommended adding NAION as a rare side effect. Experts say patients should not stop taking the medication without consulting a doctor.
Our Reading
This guidance has been heard before.
Studies show a small risk of vision loss linked to weight-loss drugs.
Companies say the risk is not proven, but regulators are watching.
Doctors say the benefits may still outweigh the risks for many.
The same concerns keep coming up, just with different names.
Author: Evan Null
